COVID-19 : Pulmonary Ultrasound in Primary Care

NCT05226403 | Completed

• 1 other identifier: 2020-A01225-34
• Study Type: observational
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

COVID-19 infection are characterized by fever and signs of acute respiratory infection. A worsening of respiratory symptoms that can lead to respiratory failure. The decompensation can then be brutal and require rapid recourse to respiratory assistance. The contribution of clinical examination (auscultation and monitoring of oxygen saturation in particular) remains unsatisfactory in predicting an unfavorable course. The interest of pulmonary ultrasound is known in the management of pulmonary infections. However, estimating the severity of lung damage at an early stage could be of great help in monitoring and caring for patients. Ultrasound could meet this need in general practice, the chest scanner is often unavailable in these situations. Ultrasound signs are associated with severe forms. The contribution of pulmonary ultrasound seems particularly interesting in the context of the reassessment of patients during the worsening phase of symptoms (D5-D10). Estimate the prevalence of ultrasound signs in patients with an acute respiratory infection suspected or confirmed to be COVID-19, at the time of the worsening phase (between D5 and D10 of the onset of symptoms). The prevalence of ultrasound lung lesions under COVID-19 may be essential to consider the development of the ultrasound tool in primary care. Indeed, if the contribution of ultrasound is now recognized in intensive care or emergency, its place in general medicine still raises questions.

Conditions

Covid19; Pulmonary Infection; Ultrasound Therapy; Complications; Respiratory Infection

Keywords

COVID19

Outcome Measures

Primary Outcomes (1)

• Ultrasound Signs

  Frequency of the presence of at least one ultrasound sign in the subjects included

  Between day 5 and day 10 of infection

Secondary Outcomes (3)

• Clinical Signs

  Day 5 and Day 10

• Ultrasound signs

  Between day 5 and day 10

• Evolution and complication

  Day 14 of infection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with acute respiratory infection linked to COVID-19

You may qualify if:

• Patients over 18 years of age with :
• a clinical symptomatology suggesting an acute respiratory infection linked to COVID-19 defined by the following two categories of symptoms:
• Sudden fever (or a feeling of fever)
• Respiratory signs (cough, dyspnea, chest tightness) Or
• an acute respiratory infection confirmed to COVID-19 by the result of RT-PCR screening tests.
• Dyspnea, shortness of breath or difficulty in breathing
• Chest pain or tightness

You may not qualify if:

• The presence of a severe form during the initial consultation. A severe form is defined by the presence of the following signs:
• Polypnea\> 22 / min
• systolic BP \<90 mmHg
• Sp02 \<90%
• Altered consciousness, confusion, drowsiness
• Dehydration
• Alteration of the general condition in the elderly
• The presence of acute respiratory signs clearly having a cause other than a COVID-19 infection.

Sponsors & Collaborators

• Geprovas: lead

Study Sites (1)

GEPROVAS

Strasbourg, 67000, France

Location

MeSH Terms

Conditions

COVID-19; Respiratory Tract Infections

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 26, 2022
• First Posted: February 7, 2022
• Study Start: July 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: February 7, 2022

Record last verified: 2022-02

Locations

FR (1)